Merck initiates Phase 3 waveLINE-010 trial for zilovertamab vedotin in diffuse large B-cell lymphoma
Merck, known as MSD outside the United States and Canada, has launched its pivotal Phase 3 waveLINE-010 clinical trial, evaluating the investigational antibody-drug conjugate (ADC) ... Read More
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration (FDA) for the treatment of relapsed or ... Read More
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More
Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102
Denovo Biopharma has secured approval from the US Food and Drug Administration (FDA) to launch its phase 2b clinical trial of DB102 in patients with ... Read More